SEC Company Response from GLYCOGENESYS INC (CIK 0000946661) — May 12, 2005
GLYCOGENESYS INC (CIK 0000946661)
Date: May 12, 2005 · CIK: 0000946661 · Accession: 0001193125-05-105108
AI Filing Summary & Sentiment
Referenced dates: May 9, 2005
Letter
VIA EDGAR Securities and Exchange Commission Department of Corporate Finance 450 Fifth Street NW Washington, DC 20549 Attention: John L. Krug, Senior Counsel
Dear Sir:
We are in receipt of a letter dated May 9, 2005 (the “letter”) from Mr. Jeffrey Riedler of the Securities and Exchange Commission (the “Commission”) to Mr. Bradley J. Carver, President and Chief Executive Officer of GlycoGenesys, Inc. (the “Company”) with respect to the Company’s Preliminary Proxy Statement on Schedule 14A filed May 4, 2005 (the “Filing”). In response to your request in the letter and on behalf of the Company, I acknowledge that (i) the Company is responsible for the adequacy and accuracy of the disclosure in the Filing, (ii) staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the Filing, and (iii) the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
GlycoGenesys, Inc.
Show Raw Text
CORRESP
1
filename1.htm
LETTER TO THE SEC
[Letterhead of GlycoGenesys, Inc.]
May 12, 2005
VIA EDGAR
Securities and Exchange Commission
Department of Corporate Finance
450 Fifth Street NW
Washington, DC 20549
Attention: John L. Krug, Senior Counsel
Dear Sir:
We are in receipt of a letter dated May 9, 2005 (the “letter”) from Mr. Jeffrey Riedler of the Securities and
Exchange Commission (the “Commission”) to Mr. Bradley J. Carver, President and Chief Executive Officer of GlycoGenesys, Inc. (the “Company”) with respect to the Company’s Preliminary Proxy Statement on Schedule 14A filed May
4, 2005 (the “Filing”). In response to your request in the letter and on behalf of the Company, I acknowledge that (i) the Company is responsible for the adequacy and accuracy of the disclosure in the Filing, (ii) staff comments or changes
to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the Filing, and (iii) the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any
person under the federal securities laws of the United States.
Sincerely,
GlycoGenesys, Inc.
By: /s/ William O. Fabbri
Name: William O. Fabbri
Title: General Counsel